When was Amnis founded?

Amnis was founded in 1998 and raised its 1st funding round 6 years after it was founded.

Where is Amnis located?

Amnis is headquartered in Seattle, United States.

How many employees does Amnis have?

As of Jul 31, 2026, the latest employee count at Amnis is 12.

Is Amnis a funded company?

Amnis is a funded company, having raised a total of $15.2M across 5 funding rounds to date. The company's 1st funding round was a $***** Unattributed round, raised on Feb 2004.

When was the latest funding round of Amnis?

Amnis' latest funding was a $***** Series C round on Jul 29, 2009, with participation from 0 investor. Its primary sector is Life Sciences Platforms and Tools. In United States, the Life Sciences Platforms and Tools sector has seen $1.23B in funding in 2026 to date.

Where does Amnis rank among its competitors?

Amnis ranks 1st amongst 12 active competitors, only 1 of which is funded. Tolemy Bio, which secured $1.65M in May, 2026.

Who are the top competitors of Amnis?

Amnis' top competitors include Tolemy Bio, Fennik Life Sciences and Human Regenerative Technologies. Among them, Tolemy Bio secured the most recent funding round in May, 2026.

Amnis - 2026 Company Profile, Funding & Competitors

Amnis is an acquired company based in Seattle (United States), founded in 1998. It operates as a Cell analysis solutions advancing cancer and cell biology research. Amnis has raised $15.2M in funding. The company has 12 active competitors, including 1 funded and 2 that have exited. Its top competitors include companies like Tolemy Bio, Fennik Life Sciences and Human Regenerative Technologies.

Company Details

Cell analysis solutions advancing cancer and cell biology research. The company provides full spectrum flow cytometry systems, reagents, and software for deep immune cell profiling. They offer a range of products including flow cytometers, reagents, and cloud-based software solutions. Services include training, validation, and design-in support. The company caters to research areas like immuno-oncology, infectious diseases, and drug discovery. They provide tools for panel design, data analysis, and experiment optimization. The company partners with software leaders to streamline workflows. They offer resources like documentation, webinars, and a user community. The company focuses on delivering benefits to scientists through innovative cell analysis solutions.

Website: amnis.com
Social
Part Of

Key Metrics

Founded Year

1998

Location

Seattle, United States

Stage

Acquired

Total Funding

$15.2M in 5 rounds

Latest Funding Round

Series C, Jul 29, 2009, $*****

Investors

Orbimed & 7 more

Ranked

1^st among 12 active competitors

Employee Count

12 as on Jul 31, 2026

Similar Companies

Tolemy Bio & 10 more

Exit Details

Acquired by EMD Millipore (Aug 30, 2011)

View Amnis' full profile

Amnis got acquired by EMD Millipore on Aug 30, 2011.

Click here to take a look at Amnis's acquisition in detail

Amnis has raised a total funding of $15.2M over 5 rounds. Its first funding round was on Feb 2004. Amnis has 8 institutional investors.

Here is the list of recent funding rounds of Amnis:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jul 29, 2009	6048895	Series C	7454174	7204072	3806467	1890538
Jan 2008	5886621	Series C	7251533	4941206	9187574	1072153
Mar 2006	1045509	Series C	6363162	2971412	6898905	TVM Capital & 4 more

Access funding benchmarks and valuations. Sign up today!

View details of Amnis's funding rounds and investors

Amnis' employee count trend

Amnis has 12 employees as of Jul 26. Here is Amnis's employee count trend over the years:

Uncover Amnis' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Amnis include Tolemy Bio, Fennik Life Sciences and Human Regenerative Technologies. Here is the list of Top 10 competitors of Amnis, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Amnis 1998, Seattle (United States), Acquired	Cell analysis solutions advancing cancer and cell biology research	$15.2M	Orbimed, Washington Research Foundation & 6 others	38/100
2nd	Tolemy Bio 2024, Barcelona (Spain), Seed	Developer of artificial intelligence software for virtual cell biological simulation	$1.65M	Norrsken Evolve, JME Venture Capital & 5 others	31/100
3rd	Fennik Life Sciences 2016, Kansas City (United States), Unfunded	Innovative 3D cell culture solutions empowering biomedical research and drug discovery	-	-	22/100
4th	Human Regenerative Technologies 2016, El Segundo (United States), Unfunded	Amniotic and placental allograft leader, advancing regenerative technologies for tissue repair	-	-	22/100
5th	Avisoft Bioacoustics 1990, Glienicke (Germany), Acquired	Manufacturer of ultrasound recording hardware and sound analysis software tools	-	-	20/100
6th	Humanrobotix 2021, United Kingdom, Unfunded	Developer of robotic interface for upper limb neuromotor research	-	-	16/100
7th	AjaxDNA Spain, Unfunded	Developer of biological intelligence software and cellular laboratory testing hardware	-	-	16/100
8th	Ishsystems 2019, West Des Moines (United States), Unfunded	Manufacturer of oxygen control systems for small animal research models	-	-	16/100
9th	Spikex United Kingdom, Unfunded	Developer of AI-powered sleep analysis system for animal research applications	-	-	16/100
10th	NeuroPulse San Diego (United States), Unfunded	Provider of neuroscientific equipment and technical support for research studies	-	-	16/100